These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10413640)

  • 1. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
    Klootwijk P; Lenderink T; Meij S; Boersma H; Melkert R; Umans VA; Stibbe J; Müller EJ; Poortermans KJ; Deckers JW; Simoons ML
    Eur Heart J; 1999 Aug; 20(15):1101-11. PubMed ID: 10413640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
    Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
    Eur Heart J; 1999 Nov; 20(22):1657-66. PubMed ID: 10543929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
    Eur Heart J; 1997 Sep; 18(9):1416-25. PubMed ID: 9458447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
    Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
    Bounameaux H; Ehringer H; Hulting J; Rasche H; Rapold HJ; Zultak M
    Thromb Haemost; 1997 Sep; 78(3):997-1002. PubMed ID: 9308743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
    PRIME CARE Study Investigators Group
    Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial.
    PRIME Investigators
    Am Heart J; 2002 Jan; 143(1):95-105. PubMed ID: 11773918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
    Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
    Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
    Direct Thrombin Inhibitor Trialists' Collaborative Group
    Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
    J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A family of arginal thrombin inhibitors related to efegatran.
    Smith GF; Shuman RT; Craft TJ; Gifford DS; Kurz KD; Jones ND; Chirgadze N; Hermann RB; Coffman WJ; Sandusky GE; Roberts E; Jackson CV
    Semin Thromb Hemost; 1996; 22(2):173-83. PubMed ID: 8807715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
    Bounameaux H; Ehringer H; Gast A; Hulting J; Rasche H; Rapold HJ; Reber G; Tschopp TB
    Thromb Haemost; 1999 Apr; 81(4):498-501. PubMed ID: 10235427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
    Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
    Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
    J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.